To improve the cancer selectivity of VV, the viral thymidine kinase (vTK) gene and/or the vaccinia growth factor (VGF) gene can be disrupted/deleted, which leads to the retention of the natural oncolytic activity of VV in cancer cells, but not in normal cells. This evidence concerns the gene VGF and cancer.